Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: Findings in an orthotopic rat xenograft model of glioma

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 33-39

  Agarwal, Sagar ^a   Manchanda, Pooja ^b   Vogelbaum, Michael A ^b   Ohlfest, John R ^a,c   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; ERLOTINIB; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CANCER INVASION; CONCENTRATION (PARAMETERS); DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TRANSPORT; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MICROVASCULATURE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; RAT; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOMA; NEOPLASM INVASIVENESS; RATS; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS; RATTUS;

EID: 84871598987     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048322     Document Type: Article

References (33)

1. Agarwal S, Hartz AM, Elmquist WF, and Bauer B (2011a) Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17:2793-2802.
2. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147-155.
3. Agarwal S, Sane R, Oberoi R, Ohlfest JR, and Elmquist WF (2011b) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17.
4. Agarwal S, Sane R, Ohlfest JR, and Elmquist WF (2011c) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223-233.
5. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, and Elmquist WF (2012) Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 40:1164-1169.
6. Bell E, Jr and Karnosh LJ (1949) Cerebral hemispherectomy; report of a case 10 years after operation. J Neurosurg 6:285-293.
7. Berens ME and Giese A (1999) "...those left behind." Biology and oncology of invasive glioma cells. Neoplasia 1:208-219.
8. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, and Supko JG; New Approaches to Brain Tumor Therapy (NABTT) Consortium (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91:51-58.
9. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
10. Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, and Elmquist WF (2009) P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 330:956-963.
11. Dai H, Marbach P, Lemaire M, Hayes M, and Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092. (Pubitemid 36254421)
12. Dandy WE (1928) Removal of right cerebral hemisphere for certain tumors with hemiplegia. J Am Med Assoc 90:823-825.
13. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, and van Tellingen O (2012) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 30:443-449.
14. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, and Stewart CF (2011) Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99.
15. Fine RL, Chen J, and Balmaceda C, et al. (2006) Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 12:5770-5776. (Pubitemid 44629608)
16. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, and Fisher J; NABTT CNS Consortium (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443-2449.
17. Hofer S and Frei K (2007) Gefitinib concentrations in human glioblastoma tissue. J Neurooncol 82:175-176. (Pubitemid 46431861)
18. Huang TT, Sarkaria SM, Cloughesy TF, and Mischel PS (2009) Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6:500-512.
19. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602. (Pubitemid 23304385)
20. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
21. Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, and Schinkel AH (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15:2344-2351.
22. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, and Schellens JH (2008) Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wildtype mice. Mol Cancer Ther 7:2280-2287.
23. Matsukado Y, MacCarty CS, and Kernohan JW (1961) The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 18:636-644.
24. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14.
25. Peereboom DM, Shepard DR, and Ahluwalia MS, et al. (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98:93-99.
26. Pitz MW, Desai A, Grossman SA, and Blakeley JO (2011) Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 104:629-638.
27. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, and Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl] aminomethyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
28. Prados MD, Chang SM, and Butowski N, et al. (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579-584.
29. Raizer JJ, Abrey LE, and Lassman AB, et al.; North American Brain Tumor Consortium (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncol 12:95-103.
30. Reardon DA, Desjardins A, and Vredenburgh JJ, et al. (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219-230.
31. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, and Aboagye EO (2009) A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 69:120-127.
32. Scherer H-J (1938) Structural development in gliomas. Am J Cancer 34:334-351.
33. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29. (Pubitemid 36078452)